ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone31-88-166-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees118
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions
What is ProQR Therapeutics' stock symbol?
ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."
How were ProQR Therapeutics' earnings last quarter?
ProQR Therapeutics NV (NASDAQ:PRQR) issued its quarterly earnings data on Wednesday, May, 8th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.05. View ProQR Therapeutics' Earnings History.
When is ProQR Therapeutics' next earnings date?
What price target have analysts set for PRQR?
6 brokers have issued twelve-month price objectives for ProQR Therapeutics' shares. Their predictions range from $20.00 to $40.00. On average, they expect ProQR Therapeutics' share price to reach $30.40 in the next year. This suggests a possible upside of 176.1% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.
What is the consensus analysts' recommendation for ProQR Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.
What are Wall Street analysts saying about ProQR Therapeutics stock?
Here are some recent quotes from research analysts about ProQR Therapeutics stock:
- 1. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (5/7/2019)
- 2. HC Wainwright analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $20.7/share, as a 25x multiple of taxed and diluted $10.07 discounted back to FY19 at 32% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $18.8/ share (discounted cash flow analysis using a 22% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (2/28/2019)
- 3. Cantor Fitzgerald analysts commented, "We think the company’s RNA-based platform for inherited eye diseases has significant potential. The company established the initial proof of concept for their approach this past September. QR-110, the company’s lead ophthalmology asset, led to meaningful vision improvements in patients with a specific type of inherited blindness called LCA10. The company is applying this approach to many additional genetic eye diseases. For instance, we model peak sales potential of $1.1B for QR-411 which are being studied in other inherited forms of blindness." (12/13/2018)
Has ProQR Therapeutics been receiving favorable news coverage?
News articles about PRQR stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ProQR Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for ProQR Therapeutics.
Who are some of ProQR Therapeutics' key competitors?
Some companies that are related to ProQR Therapeutics include Tricida (TCDA), Enanta Pharmaceuticals (ENTA), Zogenix (ZGNX), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Prestige Consumer Healthcare (PBH), Madrigal Pharmaceuticals (MDGL), Cambrex (CBM), Innoviva (INVA), Heron Therapeutics (HRTX), Nabriva Therapeutics (NBRV), Apellis Pharmaceuticals (APLS), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR) and Aimmune Therapeutics (AIMT).
What other stocks do shareholders of ProQR Therapeutics own?
Who are ProQR Therapeutics' key executives?
ProQR Therapeutics' management team includes the folowing people:
- Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 36)
- Ms. Smital Shah, Chief Bus. & Financial Officer (Age 43)
- Ms. Lisa A. Hayes, VP of Investor Relations & Corp. Communications
- Mr. Bart Klein, Sr. VP of Intellectual Property
- Mr. Gerard Platenburg, Chief Innovation Officer & Chairman of Advisory Board (Age 55)
Who are ProQR Therapeutics' major shareholders?
ProQR Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (9.08%), Jennison Associates LLC (7.43%), FMR LLC (2.47%), BlackRock Inc. (2.03%), Clearbridge Investments LLC (1.27%) and Nikko Asset Management Americas Inc. (0.74%).
Which institutional investors are selling ProQR Therapeutics stock?
PRQR stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, FMR LLC, Jennison Associates LLC, California Public Employees Retirement System and Northern Trust Corp.
Which institutional investors are buying ProQR Therapeutics stock?
PRQR stock was bought by a variety of institutional investors in the last quarter, including Nikko Asset Management Americas Inc., Goldman Sachs Group Inc., BlackRock Inc., Altrinsic Global Advisors LLC, Renaissance Technologies LLC, JPMorgan Chase & Co., Clearbridge Investments LLC and Mitsubishi UFJ Kokusai Asset Management Co. Ltd..
How do I buy shares of ProQR Therapeutics?
Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProQR Therapeutics' stock price today?
One share of PRQR stock can currently be purchased for approximately $11.01.
How big of a company is ProQR Therapeutics?
ProQR Therapeutics has a market capitalization of $427.96 million. The biopharmaceutical company earns $-43,570,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe.View Additional Information About ProQR Therapeutics.
What is ProQR Therapeutics' official website?
How can I contact ProQR Therapeutics?
ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]
MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
